
ALT CRISPR Therapeutics has presented an updated clinical data from its Phase 1b clinical trial evaluating CTX310 - CRISPR’s leading In-Vivo CRISPR Cas9 Gene Editing therapy targeting angiopoietin-like protein 3 (ANGPTL3) in patients with severe hypertriglyceridemia (sHTG). The clinical data - which was presented at the The American Heart Association Scientific Sessions, demonstrated that a single administration of CTX310 produced mean reductions from baseline at Day 30 of 65% in circulating ANGPTL3 and 63% in triglycerides (TG) in participants with a median baseline TG level above 1,000 mg/dL. These results show that a single-course treatment with CTX310 can deeply reduce ANGPTL3 and triglycerides in patients with severe hypertriglyceridemia, reinforcing its potential as a one-time “one and done” Gene Editing treatment for sHTG patients.
































